What is NMN?

NMN is nicotinamide mononucleotide, a biosynthetic precursor used by cells to make NAD+. [1][2][5]

The default oral protocol uses the lowest NMN dose from a randomized 60-day dose-ranging trial and does not borrow an NR or direct NAD+ presentation. [1][2][5]

What NMN is investigated for

NMN evidence is grouped by practical use case and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

NAD+ biomarker support

Oral

70% Moderate

Oral NAD+ biomarker restoration is the most reproducible NMN finding; it is not proof of symptom, disease, or longevity benefit. [7][8][13]

Human evidence

Randomized human studies and meta-analysis show that oral NMN increases blood NAD+ and related metabolites across several short exposure windows. [1][2][5][7][12]

Animal / mechanistic evidence

The biological rationale is supported by established NAD biosynthesis, while this confidence score is anchored to human oral biomarker studies. [1][2][5]

Glucose and metabolic health

Oral

55% Emerging

NMN is not established as a treatment for insulin resistance, diabetes, dyslipidemia, or weight loss. [7][8]

Human evidence

One randomized study in postmenopausal women with prediabetes improved muscle insulin sensitivity, but pooled randomized evidence found no consistent glucose or lipid benefit across adults. [15][7][8]

Animal / mechanistic evidence

Metabolic benefits are biologically plausible and prominent in model systems, but human results are population- and endpoint-dependent. [6][26]

Physical function and exercise performance

Oral

55% Emerging

Physical-performance effects remain limited and should not be promised for healthy users or generalized across populations. [9][10]

Human evidence

Small trials report selected aerobic-capacity, walking-speed, fatigue, or physical-performance signals, while systematic reviews find inconsistent effects across measures. [16][4][20][9][10]

Animal / mechanistic evidence

Mitochondrial and muscle rationale is stronger in preclinical models than the pooled human functional evidence. [6][26]

Vascular health

Oral

52% Emerging

NMN is not an established antihypertensive or vascular treatment. [18][11]

Human evidence

Small trials and a blood-pressure meta-analysis report heterogeneous vascular findings, with insufficient evidence for a reliable treatment effect. [18][11]

Animal / mechanistic evidence

Vascular NAD+ biology provides rationale but does not establish human blood-pressure or arterial-stiffness benefit. [6][26]

Sleep and fatigue

Oral

45% Preliminary

Sleep and fatigue benefits remain emerging and should be reassessed rather than assumed. [4][20]

Human evidence

Small older-adult trials report selected sleep-quality or fatigue signals, but endpoints, populations, and findings are not yet consistent enough for a dependable effect. [4][19][20]

Animal / mechanistic evidence

Circadian and energy-metabolism rationale is indirect and does not determine an expected clinical response. [6][26]

Healthy aging and longevity

Oral

16% Insufficient

NMN should be described as a studied NAD+ precursor, not a proven anti-aging or lifespan-extending treatment. [26][13]

Human evidence

Human trials demonstrate NAD+ biomarker engagement but not lifespan extension or broad prevention of age-related disease. [26][13]

Animal / mechanistic evidence

Aging-pathway and animal evidence motivates human study but cannot establish a human longevity effect. [6][26]

Evidence snapshot

Overall confidence

Moderate

68%

Oral NMN has multiple controlled human studies with biomarker and short-term safety data. [1][2][5]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

70%

Human evidence

Moderate

Human trials include daily 250 mg and dose-ranging 300, 600, and 900 mg regimens. [1][2][5]

30%

Animal / preclinical

Limited

Preclinical biology is extensive, but it does not replace the route-matched human oral evidence. [1][2][5]

72%

Mechanism support

Moderate

NMN is a direct biosynthetic precursor to NAD+. [1][2][5]

Forms & administration

NMN is published as one oral capsule-or-tablet entry with a 300 mg daily, 60-day default. [1]

Oral

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common oral protocols use 300 mg per day. [1]

Frequency

Usually taken once daily. [1]

Timing Considerations

Morning is the usual timing. [1]

Cycle Length

Common oral cycles run 60 days. [1]

What to expect

First 1–2 weeks

Blood NAD+ and related metabolites can rise within early study windows, but a biomarker response does not predict a noticeable clinical effect. [14][2][12]

Weeks 4–8

Many trials reassess NAD+ biomarkers, tolerability, and exploratory metabolic or physical outcomes in this range; lack of a symptom change is compatible with the evidence. [1][7][8]

Weeks 8–12

Sleep, fatigue, walking, and vascular outcomes in longer small trials are mixed and population-specific; they are not guaranteed milestones. [4][18][20]

After stopping

The durability of biomarker or symptom changes after stopping is not consistently mapped; NMN should not be assumed to create a permanent NAD+ increase. [6][13]

Safety profile

Short oral trials and recent pooled analyses generally report acceptable tolerability without a consistent excess serious-adverse-event pattern, but multi-year use, special populations, and product-to-product quality remain incompletely characterized. [1][2][17][12]

Cautions

Short-trial tolerability [1][17][12]
Dose and product identity [1][2]

What we don't know

Multi-year use, pregnancy, pediatric use, cancer-specific risk, and equivalence across formulations remain insufficiently studied. [26][13][12]

Who NMN is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding without clinician review
Pregnancy and breastfeeding safety data are insufficient for the reviewed oral use. [26][13]

Regulatory status

United States

NMN is not FDA-approved as a drug. In a September 2025 response, FDA concluded that NMN is not excluded from the dietary-supplement definition; that conclusion is not drug approval or blanket approval of individual products. [28][30]

Route	FDA drug approval	503A compounding
Oral	Not Approved NMN is not FDA-approved as a oral drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [30]	Not Listed NMN does not have FDA-approved oral dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [30]

Oral

FDA drug approval

Not Approved

NMN is not FDA-approved as a oral drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [30]

503A compounding

Not Listed

NMN does not have FDA-approved oral dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [30]

International

The European Commission has treated NMN as a novel food requiring authorization; an application or consultation status is not the same as placement on the authorized Union list. [29]

Sports & competition

Tested athletes should obtain sport-specific review for non-approved NAD-pathway products. [32]

How it works

NMN sits immediately upstream of NAD+ in the salvage pathway, which is why oral studies measure circulating NAD-related metabolites after supplementation. [1][2][5]

Oral exposure and metabolism differ from direct NAD+ administration and from nicotinamide riboside, so the molecule keeps its own dose and route record. [1][2][5]

Research gaps & open questions

What the current literature has not yet settled about NMN:

Longer controlled trials need to test clinical outcomes rather than only NAD-related biomarkers. [1][2][5]

Independent trials should compare multiple NMN amounts and better define safety in older adults and people with chronic conditions. [1][2][5]

Metabolic studies need to resolve why the muscle insulin-sensitivity signal in one population has not translated into consistent pooled glucose or lipid outcomes. [15][7][8]

Physical-function and sleep signals need replication with clearly chosen outcomes, clinically meaningful effect thresholds, and diverse populations. [9][10][20]

Multi-year safety, post-discontinuation durability, and outcomes in pregnancy, cancer, and polypharmacy remain insufficiently studied. [26][13][12]

Common questions

Is NMN direct NAD+?

No. NMN is a precursor used in NAD+ biosynthesis; direct NAD+ is a different canonical entry. [1][2][5]

Does NMN have proven anti-aging or longevity benefits?

No human trial has shown lifespan extension. NMN raises NAD-related biomarkers, but downstream clinical outcomes are mixed and generally short-term. [26][13]

Does NMN improve blood sugar or insulin resistance?

Not reliably across adults. One targeted trial improved muscle insulin sensitivity, while meta-analyses found no consistent glucose or lipid benefit. [15][7][8]

Does NMN reliably improve exercise or physical performance?

Small trials report selected signals, but pooled evidence is mixed and does not support a guaranteed performance effect. [16][9][10]

Is NMN banned as a dietary supplement in the United States?

FDA's September 2025 response concluded that NMN is not excluded from the dietary-supplement definition. That does not make NMN an FDA-approved drug or approve every product. [28]

Myths & misconceptions

Myth

NMN and NR are interchangeable names.

Reality

They are distinct NAD+ precursors with separate trial and product records. [1][2][5]

Myth

A higher blood NAD+ result proves that NMN is improving health.

Reality

Blood NAD+ is a target-engagement biomarker. Meta-analyses show that it can rise even when glucose, lipid, muscle, or other clinical outcomes do not improve. [7][8][10]

Myth

Dietary-supplement status means NMN is FDA-approved.

Reality

No. Eligibility under the dietary-supplement definition and FDA approval of a drug are different regulatory pathways. [28][30]

History & discovery

NMN is a nucleotide intermediate in NAD+ biosynthesis rather than a peptide. Human research began with short oral safety and metabolism studies, then expanded into randomized trials of NAD+ biomarkers, insulin sensitivity, physical function, vascular measures, sleep, and disease-specific questions. Biomarker engagement is more consistent than downstream clinical benefit. [6][14][26][13]

A small study in healthy men described short-term oral safety and nicotinamide-metabolite handling. [14]

Trials evaluated insulin sensitivity, aerobic capacity, sleep, physical performance, blood NAD+, and arterial stiffness. [15][16][4][18]

Meta-analyses found reliable NAD+ biomarker engagement but heterogeneous or mostly null cardiometabolic outcomes, while new disease-specific trials remained early. [7][8][23][12]

Published research 29 studies

[1]

The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

GeroScience, 2022. human clinical.

[2]

Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects

Frontiers in Nutrition, 2022. human clinical.

[3]

Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals

Nutrients, 2022. human clinical.

[4]

Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults

Nutrients, 2022. human clinical.

[5]

The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans

Nature Metabolism, 2026. human clinical.

[6]

Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions

Journal of Clinical Endocrinology & Metabolism, 2023. review.

[7]

Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials

Critical Reviews in Food Science and Nutrition, 2025. review.

[8]

Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials

Current Diabetes Reports, 2024. review.

[9]

Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide: A Systematic Review of Randomized Control Trials

Cureus, 2024. review.

[10]

The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis

Journal of Cachexia, Sarcopenia and Muscle, 2025. review.

[11]

Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Nutrients, 2026. review.

[12]

Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis

Nutrients, 2026. review.

[13]

NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

Ageing Research Reviews, 2026. review.

[14]

Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men

Endocrine Journal, 2020. human clinical.

[15]

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Science, 2021. human clinical.

[16]

Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study

Journal of the International Society of Sports Nutrition, 2021. human clinical.

[17]

Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women

Scientific Reports, 2022. human clinical.

[18]

Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial

Scientific Reports, 2023. human clinical.

[19]

Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men

Endocrine Journal, 2024. human clinical.

[20]

Ingestion of beta-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study

GeroScience, 2024. human clinical.

[21]

MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults

The Journals of Gerontology: Series A, 2023. human clinical.

[22]

Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study

Geriatrics & Gerontology International, 2023. human clinical.

[23]

Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial

Nature Medicine, 2026. human clinical.

[24]

Effect of Nicotinamide Mononucleotide on Retinal Thickness of Older Patients With Diabetes Mellitus: A Placebo-Controlled, Double-Blind Study

Geriatrics & Gerontology International, 2026. human clinical.

[25]

Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men

Scientific Reports, 2026. human clinical.

[26]

The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

Advances in Nutrition, 2023. review.

[27]

NAD+ Precursors Nicotinamide Mononucleotide and Nicotinamide Riboside: Potential Dietary Contribution to Health

Current Nutrition Reports, 2023. review.

[28]

FDA response regarding the dietary supplement status of beta-nicotinamide mononucleotide

U.S. Food and Drug Administration, 2025-09-29. regulatory.

[29]

Consultation process on novel food status: beta-nicotinamide mononucleotide

European Commission. regulatory.